Insulin Resistance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Alpelisib Pilot & Feasibility Study
Temporary Insulin Resistance
Sponsor: Dr. Joshua Cook
Enrolling: Male and Female Patients
Study Length: 4 Days
Clinic Visits: 2
IRB Number: AAAU3423
U.S. Govt. ID: NCT05733455
Contact: Zachary Sone: 212-305-9336 / zds2120@cumc.columbia.edu
Additional Study Information: We are recruiting healthy volunteers, aged 18-65, for a research study on the buildup of excessive liver fat ("fatty liver disease") in people with or at risk for type 2 diabetes because their bodies are resistant to the actions of the blood sugar-lowering hormone, insulin. To do this, we seek to induce temporary insulin resistance in 10-12 healthy volunteers using one dose of either a placebo (inactive drug) or a medication called alpelisib (brand name: Piqray), which is a treatment for certain breast cancers. We will then measure the effect of treatment on blood sugar, insulin, and fat levels during fasting and after drinking a sugary beverage. Participants will receive compensation for their participation, including a stipend (salary) of $300 and reimbursement for travel expenses.
This study is closed
Investigator
Joshua Cook, MD, PhD
Do You Qualify?
Do you have any known chronic health problems, including overweight or obesity? Yes No
Do you take any medications regularly, other than vitamin/mineral supplements or birth control? Yes No
Will you be able to attend two visits (one of 1-2 hours, and one of 4 hours) at 8:00 AM, three days apart? Yes No
Are you okay with having your blood drawn? Yes No
Are you pregnant, breastfeeding, or trying to get pregnant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Zachary Sone
zds2120@cumc.columbia.edu
212-305-9336